| Literature DB >> 34659399 |
Robert M Dietz1,2,3, James E Orfila4, Nicholas Chalmers2,3, Crystal Minjarez2,3, Jose Vigil3, Guying Deng3, Nidia Quillinan2,3, Paco S Herson4.
Abstract
Hippocampal cell death and cognitive dysfunction are common following global cerebral ischemia across all ages, including children. Most research has focused on preventing neuronal death. Restoration of neuronal function after cell death is an alternative approach (neurorestoration). We previously identified transient receptor potential M2 (TRPM2) ion channels as a potential target for acute neuroprotection and delayed neurorestoration in an adult CA/CPR mouse model. Cardiac arrest/cardiopulmonary resuscitation (CA/CPR) in juvenile (p20-25) mice was used to investigate the role of ion TRPM2 channels in neuroprotection and ischemia-induced synaptic dysfunction in the developing brain. Our novel TRPM2 inhibitor, tatM2NX, did not confer protection against CA1 pyramidal cell death but attenuated synaptic plasticity (long-term plasticity (LTP)) deficits in both sexes. Further, in vivo administration of tatM2NX two weeks after CA/CPR reduced LTP impairments and restored memory function. These data provide evidence that pharmacological synaptic restoration of the surviving hippocampal network can occur independent of neuroprotection via inhibition of TRPM2 channels, providing a novel strategy to improve cognitive recovery in children following cerebral ischemia. Importantly, these data underscore the importance of age-appropriate models in disease research.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34659399 PMCID: PMC8514917 DOI: 10.1155/2021/8774663
Source DB: PubMed Journal: Neural Plast ISSN: 1687-5443 Impact factor: 3.599
Figure 1TRPM2 inhibition does not reduce neuronal death following juvenile CA/CPR. Representative photomicrographs of hippocampal CA1 neurons after CA/CPR. Ischemic CA1 neurons were identified by hypereosinophilic cytoplasm and pyknotic nuclei and were presented as a percent of total CA1 neurons. Males were administered 20 mg/kg tatSCR (a) or tatM2NX (b), and females were administered 20 mg/kg tatSCR (c) or tatM2NX (d) 30 minutes after CA/CPR. (e) Quantification of ischemic CA1 neurons 3 days after CA/CPR. (f) Quantitative RT-PCR of TRPM2 mRNA expression in the hippocampus of adult (3-4-month-old) and juvenile (21-25-day-old) mice in both sexes.
Figure 2Acute inhibition of TRPM2 preserves LTP. (a) Time course of fEPSP slope from male juvenile mice 7 days after sham mice were administered 20 mg/kg tatSCR (black) or tatM2NX (red) 30 minutes after CA/CPR and 7 days after CA/CPR mice were administered 20 mg/kg tatSCR (blue) or tatM2NX (green) 30 min after CA/CPR. (b) Quantification of change in fEPSP slope 60 minutes after TBS stimulation normalized to 20 minutes of baseline recording. (c) Time course of fEPSP slope from female juvenile mice 7 days after sham mice were administered 20 mg/kg tatSCR (black) or tatM2NX (red) 30 minutes after CA/CPR and 7 days after CA/CPR mice were administered 20 mg/kg tatSCR (blue) or tatM2NX (green) 30 min after CA/CPR. (d) Quantification of change in fEPSP slope 60 minutes after TBS stimulation normalized to 20 minutes of baseline recording (set at 100%). Each point represents one hippocampal slice, with no more than 2 slices from an individual mouse. ∗p < 0.05 by one-way ANOVA.
Figure 3Delayed inhibition of TRPM2 with tatM2NX restores synaptic plasticity. (a) Time course of fEPSP slope 14 days after sham mice were treated on day 13 with 20 mg/kg tatSCR (black) or tatM2NX (red) and 14 days after CA/CPR mice were treated on day 13 with 20 mg/kg tatSCR (blue) or tatM2NX (green). (b) Quantification of change in fEPSP slope 60 minutes after TBS stimulation normalized to 20 minutes of baseline recording (set at 100%). Each point represents one hippocampal slice, with no more than 2 slices from an individual mouse. ∗p < 0.05 by one-way ANOVA.
Figure 4Delayed inhibition of TRPM2 restores memory function. (a) Quantification of freezing behavior 24 hours after contextual fear conditioning in a novel environment in mice administered 20 mg/kg tatSCR (black) or 20 mg/kg tatM2NX (red) after sham surgery or mice administered 20 mg/kg tatSCR (blue) or 20 mg/kg tatM2NX (green) 13 days after recovery from CA/CPR and behavior testing initiated on day 14 after CA/CPR. (b) Quantification of distance traveled in the same mice as in (a) in open field testing, indicating no changes in locomotion to account for differences in freezing. Each point represents 1 mouse, and ∗p < 0.05 by one-way ANOVA.